# VER001

Source: https://onco.cc/drugs/ver001/  
OnCo record `ver001` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

VER001 is an experimental tablet form of fulvestrant from VeraMorph, for hormone receptor-positive breast cancer that has spread. It is in laboratory testing.

## Summary

VER001 is VeraMorph's oral formulation of fulvestrant, made with its DPOD delivery platform, intended for oestrogen receptor-positive metastatic breast cancer. NCI SBIR award 4R44CA306533-02 funds its preclinical validation. No human data have been published.

## Fields

- Kind: Treatment
- Status: preclinical
- Last checked: 2026-11-04
- Also known as: Oral fulvestrant (VeraMorph)
- Tags: pipeline
- Code: VER001
- Modality: Oral selective oestrogen receptor degrader (fulvestrant reformulation)
- Mechanism: Fulvestrant binds the oestrogen receptor and causes it to be degraded; VER001 is a formulation intended to deliver it by mouth rather than by injection.

## Sources

- VeraMorph: product portfolio: https://www.veramorph.com/portfolio

## Connected records

- technologies: [Oral SERDs](https://onco.cc/technologies/oral-serds/)
- targets: [Estrogen receptor (ERα)](https://onco.cc/targets/estrogen-receptor/)
- companies: [VeraMorph](https://onco.cc/companies/veramorph/)

---
JSON: https://onco.cc/api/v1/entities/ver001.json